Sei Investments Co. Has $1.42 Million Stock Holdings in Design Therapeutics, Inc. $DSGN

Sei Investments Co. increased its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) by 152.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 133,203 shares of the company’s stock after acquiring an additional 80,473 shares during the period. Sei Investments Co.’s holdings in Design Therapeutics were worth $1,417,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its position in Design Therapeutics by 45.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 431,840 shares of the company’s stock worth $4,593,000 after purchasing an additional 133,919 shares during the last quarter. AlphaCentric Advisors LLC lifted its holdings in shares of Design Therapeutics by 4.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 21,231 shares of the company’s stock valued at $226,000 after buying an additional 969 shares during the last quarter. Strs Ohio grew its stake in shares of Design Therapeutics by 77.4% in the 1st quarter. Strs Ohio now owns 44,700 shares of the company’s stock valued at $476,000 after buying an additional 19,500 shares in the last quarter. Corient Private Wealth LLC bought a new stake in shares of Design Therapeutics in the 4th quarter valued at approximately $253,000. Finally, Virtu Financial LLC acquired a new position in Design Therapeutics in the fourth quarter worth approximately $212,000. Institutional investors and hedge funds own 56.64% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on DSGN. Wall Street Zen raised shares of Design Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Cantor Fitzgerald assumed coverage on shares of Design Therapeutics in a research note on Tuesday, May 12th. They set an “overweight” rating on the stock. Piper Sandler restated an “overweight” rating and set a $20.00 price target on shares of Design Therapeutics in a report on Wednesday, April 29th. Oppenheimer lifted their price objective on shares of Design Therapeutics from $18.00 to $21.00 and gave the company an “outperform” rating in a research note on Monday, May 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Design Therapeutics in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

Design Therapeutics Trading Up 2.4%

Shares of Design Therapeutics stock opened at $14.33 on Tuesday. The firm has a fifty day simple moving average of $12.79 and a 200-day simple moving average of $11.87. The stock has a market capitalization of $896.77 million, a price-to-earnings ratio of -12.14 and a beta of 1.63. Design Therapeutics, Inc. has a 1-year low of $4.23 and a 1-year high of $17.25.

Design Therapeutics (NASDAQ:DSGN) last announced its earnings results on Monday, August 3rd. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.02. As a group, research analysts predict that Design Therapeutics, Inc. will post -1.41 earnings per share for the current year.

Design Therapeutics Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.